Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Unternehmen & Branche
| Name | Revolution Medicines, Inc. |
|---|---|
| Ticker | RVMD |
| CIK | 0001628171 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 29,49 Mrd. USD |
| Beta | 1,01 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -1,131,301,000 | -5.95 | 2,354,508,000 | 1,631,297,000 |
| 2025-09-30 | 10-Q | -305,206,000 | -1.61 | 2,251,920,000 | 1,596,904,000 | |
| 2025-06-30 | 10-Q | -247,787,000 | -1.31 | 2,429,568,000 | 1,865,369,000 | |
| 2025-03-31 | 10-Q | -213,416,000 | -1.13 | 2,365,353,000 | 2,078,150,000 | |
| 2024-12-31 | 10-K | 0 | -600,093,000 | -3.58 | 2,558,301,000 | 2,265,204,000 |
| 2024-09-30 | 10-Q | 0 | -156,288,000 | -0.94 | 1,762,999,000 | 1,566,304,000 |
| 2024-06-30 | 10-Q | 0 | -133,233,000 | -0.81 | 1,808,437,000 | 1,618,848,000 |
| 2024-03-31 | 10-Q | 0 | -116,003,000 | -0.70 | 1,908,362,000 | 1,725,467,000 |
| 2023-12-31 | 10-K | 11,580,000 | -436,367,000 | -3.86 | 2,061,705,000 | 1,826,194,000 |
| 2023-09-30 | 10-Q | 0 | -108,434,000 | -0.99 | 984,232,000 | 837,458,000 |
| 2023-06-30 | 10-Q | 3,824,000 | -98,298,000 | -0.92 | 1,073,709,000 | 930,835,000 |
| 2023-03-31 | 10-Q | 7,014,000 | -68,098,000 | -0.72 | 1,073,248,000 | 952,218,000 |
| 2022-12-31 | 10-K | 35,380,000 | -248,705,000 | -3.08 | 811,930,000 | 685,188,000 |
| 2022-09-30 | 10-Q | 3,356,000 | -73,329,000 | -0.87 | 825,910,000 | 681,419,000 |
| 2022-06-30 | 10-Q | 9,116,000 | -61,222,000 | -0.82 | 632,802,000 | 498,841,000 |
| 2022-03-31 | 10-Q | 7,578,000 | -57,647,000 | -0.78 | 682,774,000 | 550,993,000 |
| 2021-12-31 | 10-K | 29,390,000 | -187,091,000 | -2.57 | 737,988,000 | 602,568,000 |
| 2021-09-30 | 10-Q | 1,101,000 | -52,940,000 | -0.72 | 734,976,000 | 638,204,000 |
| 2021-06-30 | 10-Q | 8,698,000 | -44,299,000 | -0.60 | 774,046,000 | 685,006,000 |
| 2021-03-31 | 10-Q | 10,131,000 | -37,176,000 | 811,651,000 | 722,580,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -1,671 | 131.66 | -220,007.03 | -11,8% | |
| 2026-04-27 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -400 | 134.34 | -53,734.00 | -2,9% | |
| 2026-04-27 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -1,049 | 132.88 | -139,387.76 | -7,5% | |
| 2026-04-15 | GOLDSMITH MARK A | Director, Officer, See Remarks | Open Market Sale | -120,000 | 150.09 | -18,010,488.00 | -965,1% | |
| 2026-03-25 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -21,086 | 95.49 | -2,013,415.69 | -107,9% | |
| 2026-03-25 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -11,036 | 96.43 | -1,064,200.38 | -57,0% | |
| 2026-03-25 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -400 | 97.21 | -38,882.84 | -2,1% | |
| 2026-03-25 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -1,800 | 93.22 | -167,801.40 | -9,0% | |
| 2026-03-25 | Mancini Anthony | Officer, See Remarks | Open Market Sale | -3,128 | 94.16 | -294,520.28 | -15,8% | |
| 2026-03-17 | Wei Lin | Officer, Chief Medical Officer | Open Market Sale | -2,073 | 99.48 | -206,222.87 | -11,1% | |
| 2025-09-16 | Wei Lin | Officer, Chief Medical Officer | Open Market Sale | -2,160 | 45.82 | -98,981.78 | -5,3% | |
| 2025-06-16 | Wei Lin | Officer, Chief Medical Officer | Open Market Sale | -2,173 | 39.83 | -86,550.59 | -4,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.